Last reviewed · How we verify

Amgen Research (Munich) GmbH — Portfolio Competitive Intelligence Brief

Amgen Research (Munich) GmbH pipeline: 0 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 2 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Allergan · 1 shared drug class
  2. Amgen · 1 shared drug class
  3. Bayer · 1 shared drug class
  4. Beijing Anzhen Hospital · 1 shared drug class
  5. CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · 1 shared drug class
  6. Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III · 1 shared drug class
  7. Hospital General Universitario Gregorio Marañon · 1 shared drug class
  8. Novartis · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Amgen Research (Munich) GmbH:

Cite this brief

Drug Landscape (2026). Amgen Research (Munich) GmbH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/amgen-research-munich-gmbh. Accessed 2026-05-16.

Related